List of Forum topics for 2019. For additional information, contact: AMCP’s Strategic Alliances & Corporate Services Office | busdevelopment@amcp.org | (703) 684-2616
On October 30, 2018, CMS published an Advanced Notice of Proposed Rulemaking for a potential International Pricing Index (IPI) Model for Medicare Part B Drugs. The model would be phased in over a five-year period and will be tested as a pilot program through the CMS Center for Medicare and Medicaid Innovation. The model is intended to lower expenditures for Part B drugs by implementing an international reference price to shift payments to a level that is comparable with prices in other countries. It also seeks to reform the current “buy and bill” system for Part B drugs and alter reimbursement methodology to eliminate existing incentives to prescribe higher-cost drugs.
AMCP webinar that reviewed AMCP’s activity related to preapproval information exchange (PIE) and provided the payer and manufacturer perspective on the important and usefulness of PIE.
On October 18, 2018, CMS issued a new proposed rule that would require direct-to-consumer (DTC) television advertisements of prescription drugs and biological products payable by Medicare or Medicaid to include the wholesale acquisition cost (WAC), or list price, of that prescription drug or biological product.
Opioid Legislation Reaches Final Agreement--September 2018 With a final compromise bill for the opioid package announced, AMCP would like to thank its members who acted to advocate for the inclusion of provisions which will help managed care combat the opioid crisis. Almost 300 AMCP members sent letters to 62 Senators
On September 21, 2018, AMCP offered comments to the FDA on facilitating biosimilar adoption and the interchangeability designation. Comments focused on interchangeability guidance, naming conventions, and collection of post-marketing real-world evidence by partnering with organizations such as Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).